Response to Lu et al.
A recent Swedish 10-year follow-up study of elderly men (mean age 71 years) (5) showed that plasma PTH level, even in the normal range, was associated with a higher risk of cardiovascular mortality, even after adjustments for established cardiovascular risk factors and vitamin D deficiency.
Future observational studies addressing the association between vitamin D and cardiovascular risk should therefore include PTH and calcium in their analyses. Although a recently published randomized controlled trial (6) could not demonstrate that vitamin D supplementation has a significant effect on the glucose metabolism of subjects with type 2 diabetes, sufficiently powered and welldesigned randomized controlled clinical trials (including therapeutic strategies to increase 25[OH]D levels and lower PTH levels, e.g., calcium/vitamin D supplementation or calcimimetics, the therapeutic drugs demonstrated to lower PTH levels through an increase in the intracellular calcium of parathyroid cells) are needed to explore any cause-and-effect relationships.
